STAT (6/26, Facher, Subscription Publication) reports a study found that “compared to white patients, Black and Hispanic patients were 17.1% and 16.2% less likely, respectively, to receive either buprenorphine or naltrexone within 180 days of a health care event related to their substance use, like a nonfatal overdose or addiction-related infection.” The study is the first to “analyze data from multiple payers at once,” as it includes “data from roughly 176,000 health events related to substance use, and tracks receipt of medication based on claims data from Medicaid programs, Medicare Advantage, and private commercial insurers.” In addition, researchers found that “patients using either of the government-backed insurance options – Medicaid or Medicare Advantage – were substantially more likely to receive buprenorphine or naltrexone than those with commercial insurance.” The study was published in JAMA Network Open.
Related Links:
— “Black, Hispanic patients significantly less likely to receive key addiction medications, study finds,” Lev Facher, STAT, June 26, 2025